Goldline Pharmaceutical Ltd (544759)
🎯 Key Takeaways
- Goldline Pharmaceutical Ltd appears to be in a mature, cash-generating phase with minimal capital intensity and stable governance structures, supported by consistent profitability and promoter-backed financial discipline. The company operates with low leverage (D/E of 0.
- ⚠️ The company's small scale and concentrated ownership may limit liquidity and increase volatility. Heavy reliance on a narrow operational base is expos
📖 The Story
Goldline Pharmaceutical Ltd appears to be in a mature, cash-generating phase with minimal capital intensity and stable governance structures, supported by consistent profitability and promoter-backed financial discipline. The company operates with low leverage (D/E of 0.74) and has demonstrated steady financial performance, though scale remains modest, with revenue of ₹3,119.88 lakhs and profit of ₹411.71 lakhs reported in FY2025-26.
📰 What's Happening
In late August 2026, the company conducted its 22nd AGM, where shareholders approved the FY2025-26 financials and declared a ₹12 dividend per preference share, reflecting confidence in ongoing profitability. Management highlighted strategic focus on expanding customer base and strengthening market presence for FY2026-27. Concurrently, promoter Swapan Khandelwal acquired 78,000 shares, increasing his stake to 0.81%, signaling alignment with shareholder value at current valuations.
Source: Stock Announcements
🔮 Management Outlook & What's Next
Management expressed a forward-looking focus on sustainable growth, customer base expansion, and market presence strengthening in FY2026-27, though no specific revenue or margin targets were disclosed. The tone was measured, emphasizing governance and continuity rather than aggressive scaling, consistent with the company's small-cap profile and niche operational footprint.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Equity Capital | 7 |
| Reserves | 6 |
| Borrowings | 9 |
| Total Liabilities | 29 |
| Fixed Assets | 3 |
| Investments | 0 |
| Total Assets | 29 |
The balance sheet indicates a highly conservative capital structure with negligible debt and a small asset base, suggesting limited reinvestment capacity or strategic appetite. Equity and reserves remain stable, with borrowings at ₹9 lakhs, implying a preference for organic growth financing through internal cash flows rather than external leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +3 |
| Investing | -0 |
| Financing | -3 |
| Net Cash Flow | -1 |
👥 Shareholding Pattern
| Category | Q2FY26 |
|---|---|
| Promoters | 79.7% |
| FII | 0.0% |
| DII | 0.0% |
| Public | 0.0% |
| # Shareholders | 20 |
Promoter holding stands at 79.71% with no public or institutional ownership disclosed, and a recent insider purchase by Whole Time Director Swapan Khandelwal reinforces confidence among key stakeholders. The shareholder base is concentrated, with 20 retail shareholders, and no FII/DII activity reported, suggesting limited external scrutiny or institutional interest to date.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.63 L Cr | 38.3 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.43 L Cr | 83.2 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.1 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.15 L Cr | 34.0 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.00 L Cr | 91.8 | 20.8% | 20.6% | 0.45 |
| LUPIN | 98,305 | 17.4 | 27.9% | 24.7% | 0.26 |
| DRREDDY | 97,741 | 30.3 | 10.1% | 8.4% | 0.17 |
| MANKIND | 97,467 | 47.7 | 13.9% | 12.7% | 0.38 |
| AUROPHARMA | 96,836 | 26.3 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
The company's small scale and concentrated ownership may limit liquidity and increase volatility. Heavy reliance on a narrow operational base is exposed to sector-specific headwinds, though no regulatory or compliance risks were flagged in filings. Management has not articulated a clear growth roadmap beyond general expansion goals, leaving execution risk unquantified.
📋 Recent Filings
-
🔴 Insider Trading 1 September 2026Goldline Pharmaceutical disclosed that promoter and Managing Director Amol Laxmikant Mujumdar acquired 60000 shares at 0.62% of total issued capital o...
-
🟡 voting results 31 August 2026Goldline Pharmaceutical held its AGM on 29 August 2026, appointing CS Avinash Gandhewar as scrutinizer. All 8 resolutions passed with 100% approval ac...
-
🔴 Insider Trading 29 August 2026Goldline Pharmaceutical disclosed that promoter and Whole Time Director Mr. Swapan Khandelwal acquired 78,000 shares at [amount not verified]each, inc...
-
🟡 Board Meeting 29 August 2026Goldline Pharmaceutical held its 22nd AGM on August 29, 2026 in Nagpur, adopting FY2025-26 financials with revenue rising to ₹3,119.88 lakhs and profi...
🧠 Analyst's Read
Goldline Pharmaceutical operates as a stable, low-debt entity with consistent profitability and promoter-aligned governance, but lacks visible scalability or external investor engagement. The next watchpoint is whether management can translate strategic intent into measurable growth without diluting margins or increasing leverage.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd